Comparative Pharmacology
Head-to-head clinical analysis: LOXAPINE SUCCINATE versus TINDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXAPINE SUCCINATE versus TINDAL.
LOXAPINE SUCCINATE vs TINDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine is a dibenzoxazepine antipsychotic that exerts its effects primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors. It also has moderate affinity for histamine H1, alpha-1 adrenergic, and muscarinic acetylcholine receptors.
TINDAL (trimethoprim) inhibits bacterial dihydrofolate reductase (DHFR), preventing the reduction of dihydrofolate to tetrahydrofolate, thereby inhibiting bacterial DNA synthesis.
Initial: 10 mg twice daily orally; increase to 25-50 mg twice daily over 7-10 days; maximum 250 mg/day. IM: 12.5-50 mg every 4-6 hours.
TINDAL (ticarcillin disodium + clavulanate potassium) 3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours. Maximum dose: 18 g ticarcillin/0.6 g clavulanic acid per day.
None Documented
None Documented
Terminal elimination half-life: 12–19 hours (mean 16 hours) after oral administration; steady-state reached within 3–5 days.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment.
Renal (approximately 60% as metabolites, <1% unchanged) and fecal (approximately 40% as metabolites).
Primarily renal excretion of unchanged drug (70-80%) and hepatic metabolism (20-30%).
Category C
Category C
Antipsychotic
Antipsychotic